کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2942084 1177100 2008 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents : Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents : Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
چکیده انگلیسی

ObjectivesThis study evaluates outcomes and complications in patients treated with drug-eluting stents (DES) for “off-label” indications.BackgroundDrug-eluting stents have been effective in randomized trials, but their safety and efficacy for off-label indications has not been well studied.MethodsThe STENT (Strategic Transcatheter Evaluation of New Therapies) Registry is the largest multicenter U.S. registry evaluating outcomes of DES. Off-label indications included ostial, left main, long, bifurcation, and in-stent restenotic lesions, saphenous vein grafts, chronic total occlusions, small or large vessels, multilesion or multivessel percutaneous coronary interventions, and ST-segment elevation myocardial infarction. Outcomes were adjusted using Cox proportional hazards regression and propensity analyses.ResultsDrug-eluting stents were used in an off-label manner in 59% of patients. The patients who received off-label treatment were more often male, had a higher incidence of prior infarction and bypass surgery, and lower ejection fractions. Off-label versus “on-label” use of DES was associated with higher rates of death, myocardial infarction, target vessel revascularization, major adverse cardiac events, and stent thrombosis at 9 months and 2 years. Off-label use of DES compared with off-label use of bare-metal stents (BMS) had lower rates of death, myocardial infarction, target vessel revascularization, and major adverse cardiac events at 9 months and 2 years and lower rates of stent thrombosis at 9 months.ConclusionsOff-label use of DES is associated with higher event rates compared with on-label use of DES, which is consistent with a higher risk clinical and lesion profile. However, event rates with off-label use of DES are lower compared with off-label use of BMS. Pending results from randomized trials, our data support the use of DES for off-label indications in selected patients.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: JACC: Cardiovascular Interventions - Volume 1, Issue 4, August 2008, Pages 405–414
نویسندگان
, , , , , , , , , , , , , , ,